Beck Mack & Oliver’s GSK GSK Stock Holding History

Beck Mack & Oliver’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-4,798	Closed	-$244K	–	233
2017 Q3	$244K	Hold	4,798	–	–	0.01%	200
2017 Q2	$259K	Hold	4,798	–	–	0.01%	196
2017 Q1	$253K	Hold	4,798	–	–	0.01%	194
2016 Q4	$231K	Sell	4,798 -620	-11%	-$30.6K	0.01%	198
2016 Q3	$292K	Hold	5,418	–	–	0.01%	188
2016 Q2	$294K	Hold	5,418	–	–	0.01%	225
2016 Q1	$275K	Sell	5,418 -4,240	-44%	-$211K	0.01%	225
2015 Q4	$487K	Sell	9,658 -1,054	-10%	-$53.7K	0.02%	195
2015 Q3	$515K	Sell	10,712 -3,350	-24%	-$174K	0.02%	215
2015 Q2	$732K	Hold	14,062	–	–	0.02%	201
2015 Q1	$811K	Hold	14,062	–	–	0.02%	196
2014 Q4	$751K	Buy	14,062 +14	+0.1%	+$783	0.02%	198
2014 Q3	$807K	Hold	14,048	–	–	0.02%	202
2014 Q2	$939K	Hold	14,048	–	–	0.02%	182
2014 Q1	$938K	Sell	14,048 -248	-2%	-$16.8K	0.02%	183
2013 Q4	$954K	Sell	14,296 -1,672	-10%	-$108K	0.02%	187
2013 Q3	$1M	Sell	15,968 -146	-0.9%	-$9.4K	0.03%	174
2013 Q2	$1.01M	Buy	+16,114	New	+$1.02M	0.03%	170

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Beck Mack & Oliver's GSK Position: Q4 2017 in Review

Beck Mack & Oliver sold out of GSK (GSK) in Q4 2017, closing a stake of 4,798 shares — an estimated $244K sold.

Beck Mack & Oliver first reported a position in GSK in Q2 2013 and held it in 18 quarters. The position peaked at $1.01M in Q2 2013. 763 funds tracked by Wall St. Rank hold GSK as of Q4 2017.

Beck Mack & Oliver reported no remaining GSK position as of Q4 2017 after selling out during the quarter.
Beck Mack & Oliver sold 4,798 GSK shares in Q4 2017, an estimated $244K.
Beck Mack & Oliver first reported a position in GSK in Q2 2013 and held it in 18 quarters.
Beck Mack & Oliver's GSK position peaked at $1.01M in Q2 2013.
763 funds tracked by Wall St. Rank held GSK as of Q4 2017.

Based on Beck Mack & Oliver's 13F filing for Q4 2017, filed 2 Feb 2018.